Arteriovenous Malformations Clinical Trial
Official title:
A Modular Open Label, Signal Seeking, Phase II Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations (TARGET-VM)
Recent studies have demonstrated that growth of vascular malformations can be driven by genetic variants in one of 2 signalling pathways. Targeted drugs specific to these pathways have been developed and shown to be effective in treating cancer. This study will describe the effectiveness of (i) 48 weeks of alpelisib therapy for participants with slow-flow vascular malformations and a gene mutation in one of these signalling pathways (module 1) and (ii) 48 weeks of mirdametinib therapy for participants with fast-flow vascular malformations and a gene mutations in the other signalling pathway (module 2).
TARGET-VM is a modular open-label, signal seeking, phase II trial of targeted therapies for patients with vascular malformations. Patients with vascular malformations which are refractory to standard therapies, or in whom standard therapy is not appropriate, are potentially eligible for the clinical trial. Vascular malformations will be classified as slow-flow or fast-flow lesions using established clinical criteria. Genetic testing to identify causative variants in genes affecting the phosphoinositide 3-kinase (PI3K) signalling pathway for slow-flow vascular malformations or the Mitogen-Activated Protein Kinase (MAPK) signalling pathway for fast-flow vascular malformations must be performed using research protocols or commercial testing assays that are external to this clinical trial. The study consists of individual modules, each evaluating the clinical efficacy of 48 weeks of targeted therapy. The treatment modules are: 1. Module 1 - Treatment for slow-flow vascular malformations Eligible patients with slow-flow vascular malformations with an identified causative variant in the PI3K signalling pathway will receive alpelisib, an oral alpha-specific PI3-kinase inhibitor for a total duration of 48 weeks as monotherapy (treatment period), followed by 24 weeks of follow-up (follow-up period). 2. Module 2 - Treatment for fast-flow vascular malformations Eligible patients with fast-flow vascular malformations with an identified causative variant in the MAPK signalling pathway will receive mirdametinib, an investigational oral MEK inhibitor for a total duration of 48 weeks as monotherapy (treatment period), followed by 24 weeks of follow-up (follow-up period). TARGET-VM will be conducted only in Victoria, Australia. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03306836 -
Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 2
|
N/A | |
Recruiting |
NCT03306823 -
Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 1
|
N/A | |
Completed |
NCT01347307 -
Stereotactic Body Radiotherapy for Spine Tumors
|
N/A | |
Recruiting |
NCT02042326 -
Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations
|
Phase 2 | |
Recruiting |
NCT05484245 -
Sonography-guided Resection of Brain Mass Lesions
|
N/A | |
Recruiting |
NCT05484219 -
Functional Navigation in Surgery of Cerebral Tumors and Vascular Malformations
|
N/A | |
Recruiting |
NCT05477680 -
Intraoperative Brain Shift Calculation Study
|
N/A | |
Completed |
NCT03656211 -
Fertility After Diagnosis and Management of Acquired Uterine Arteriovenous Malformation
|
||
Completed |
NCT04246125 -
Patient Skin Dose in Interventional Radiology
|
||
Recruiting |
NCT02879071 -
Long Term Follow-up After Embolization of Brain Arteriovenous Malformations
|
||
Terminated |
NCT01801488 -
Genome-wide Analysis of Single Nucleotide Polymorphisms of Brain Arteriovenous Malformations and Cerebral Aneurysm
|
N/A | |
Recruiting |
NCT06259292 -
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
|
||
Recruiting |
NCT02098252 -
Treatment of Brain AVMs (TOBAS) Study
|
N/A | |
Completed |
NCT02378883 -
Apollo™ Onyx™ Delivery Microcatheter Post Market Safety Study
|
N/A | |
Completed |
NCT00783523 -
Influence of MMP on Brain AVM Hemorrhage
|
Phase 1 | |
Recruiting |
NCT05276934 -
Brain Imaging After Non-traumatic Intracranial Hemorrhage (SAVEBRAINPWI)
|
||
Recruiting |
NCT03031873 -
Evaluation of Susceptibility-weighted Magnetic Resonance Imaging and 4d-time-resolved Magnetic Resonance Angiography in Brain Arteriovenous Malformations
|
N/A | |
Withdrawn |
NCT02079818 -
Visceral Artery Aneurysm Embolization by the Penumbra Ruby™ Coil System
|
Phase 4 | |
Completed |
NCT01381952 -
Image Quality and Radiation Dose in Angiography
|
N/A | |
Active, not recruiting |
NCT05418816 -
SelfWrap-Assisted Arteriovenous Fistulas
|
N/A |